Scoop: Ab­b­Vie ter­mi­nates ear­ly-stage study of I-Mab's an­ti­body, an­oth­er clin­i­cal set­back in CD47 field

The CD47 field faced set­backs ear­li­er this year when Gilead’s ma­grolimab was hit with par­tial clin­i­cal holds, and an­oth­er clin­i­cal hur­dle can be added to the list, with Ab­b­Vie ter­mi­nat­ing a study of an an­ti­body out of part­ner I-Mab.

The nixed study was ex­plor­ing the IV drug lem­zopar­limab in com­bi­na­tion with or with­out an oral or IV for­mu­la­tion of dex­am­etha­sone and in com­bi­na­tion with an­ti-myelo­ma reg­i­mens in adults with mul­ti­ple myelo­ma. The tri­al be­gan in Jan­u­ary and had been slat­ed for a Ju­ly 2025 com­ple­tion, but Ab­b­Vie end­ed up on­ly en­rolling eight pa­tients with the white blood cell can­cer out of an orig­i­nal­ly planned 163, ac­cord­ing to the fed­er­al tri­als data­base.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER